Pädiatrische epileptische Enzephalopathien mit Manifestation oberhalb des Neugeborenenalters: ein Up-date

Regina Trollmann; Ingo Borggräfe; Wolfgang Müller-Felber; Ulrich Brandl

doi:10.1055/a-1528-3511

Klinische Neurophysiologie, Inhaltsverzeichnis

Klinische Neurophysiologie 2021; 52(03): 167-179
DOI: 10.1055/a-1528-3511

Übersicht

Pädiatrische epileptische Enzephalopathien mit Manifestation oberhalb des Neugeborenenalters: ein Up-date

Update on Epileptic Encephalopathies of Infancy and Childhood

Regina Trollmann

¹Abteilung Neuropädiatrie und Sozialpädiatrisches Zentrum, Kinder-und Jugendklinik am Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen

,

Ingo Borggräfe

²Abteilung für Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Dr. von Haunersches Kinderspital, LMU Klinikum München, München

³Interdisziplinäres Epilepsiezentrum, LMU Klinikum München, München

,

Wolfgang Müller-Felber

²Abteilung für Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Dr. von Haunersches Kinderspital, LMU Klinikum München, München

,

Ulrich Brandl

⁴Klinik für Neuropädiatrie, Universitätsklinikum Jena, Jena

› Institutsangaben

Abstract

Zusammenfassung

Entwicklungs-und epileptische Enzephalopathien manifestieren sich überwiegend bereits im Säuglings-und frühen Kleinkindesalter. Mit der neuen ILAE-Klassifikation der Epilepsien konnten epileptische Enzephalopathien sowohl hinsichtlich des elektroklinischen Phänotyps als auch des ätiologischen Spektrums und assoziierter Komorbiditäten genauer definiert werden. Einige elektroklinischer Entitäten wie das West-Syndrom oder das Dravet-Syndrom können auf der Basis ihres Genotyps inzwischen als spezifische Enzephalopathien klassifiziert werden. Das EEG stellt eine wichtige Zusatzdiagnostik in der Abklärung einer epileptischen Enzephalopathie dar. Es hat einen besonderen Stellenwert für die Diagnose von Komplikationen wie z. B. subklinischer Anfälle oder eines Status epilepticus sowie für ein adäquates Therapiemonitoring. Der Betrag fasst anhand ausgewählter pädiatrischer Epilepsiesyndrome aktuelle Aspekte zur Komplexität der pädiatrischen epileptischen Enzephalopathien und den Stellenwert der EEG-Diagnostik zusammen.

Abstract

Developmental and epileptic encephalopathies represent complex and neurodegenerative disorders characterized by onset of refractory seizures usually in the first year of life and associated with motor and intellectual disability. The new ILAE classification of seizures and epilepsies proposed a revised definition of epileptic encephalopathies including electro-clinical phenotype as well as etiological spectrum and associated comorbidities. Modern genetic techniques led to the identification of a precise genotype in several electro-clinical syndromes such as West syndrome and Dravet syndrome. EEG continues to play a specific role as an additional tool in diagnosis and management of epileptic encephalopathies with special focus on the diagnosis of complications such as subclinical seizures and status epilepticus as well as treatment monitoring. This article reviews current aspects of complex pediatric epileptic encephalopathies and the significance of EEG monitoring.

Schlüsselwörter

West-Syndrom - Dravet-Syndrom - Landau-Kleffner-Syndrom - CSWS - Lennox-Gastaut-Syndrom

Key words

West syndrome - Dravet syndrome - Landau-Kleffner syndrome - CSWS - Lennox-Gastaut syndrome

Volltext

Referenzen

Literatur
1 Fisher RS, Cross JH, French JA. et al Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 522-530
2 Scheffer IE, Berkovic S, Capovilla G. et al ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512-521
3 Symonds JD, McTague A. Epilepsy and developmental disorders: Next generation sequencing in the clinic. Eur J Paediatr Neurol 2020; 24: 15-23
4 Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia 2019; 60: S59-S67
5 Jozwiak S, Kotulska K, Wong M. et al Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex. Neuropharmacology 2020; 166: 107908
6 Nariai H, Hussain SA, Bernardo D. et al Scalp EEG interictal high frequency oscillations as an objective biomarker of infantile spasms. Clin Neurophysiol 2020; 131: 2527-2536
7 Lux AL. Latest American and European updates on infantile spasms. Curr Neurol Neurosci Rep 2013; 13: 334-341
8 Pavone P, Polizzi A, Marino SD. et al West syndrome: a comprehensive review. Neurol Sci 2020; 41: 3547-3562
9 Wirrell EC, Shellhaas RA, Joshi C. et al How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia 2015; 56: 617-625
10 Kothare SV, Singh K, Chalifoux JR. et al Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 2014; 55: 1025-1029
11 Popp B, Trollmann R, Büttner C. et al Do the exome: A case of Williams-Beuren syndrome with severe epilepsy due to a truncating de novo variant in GABRA1. Eur J Med Genet 2016; 59: 549-553
12 Riikonen R, Rener-Primec Z, Carmant L. et al Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015; 57: 60-67
13 O'Callaghan FJK, Edwards SW, Alber FD. et al Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health 2018; 2: 715-725
14 Samueli S, Dressler A, Gröppel G. et al Everolimus in infants with tuberous sclerosis complex-related West syndrome: First results from a single-center prospective observational study. Epilepsia 2018; 59: e142-e146
15 French JA, Lawson JA, Yapici Z. et al Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388: 2153-2163
16 Riikonen R. Infantile spasms: outcome in clinical studies. Pediatr Neurol 2020; 20: 30041-30042
17 Yuskaitis CJ, Ruzhnikov MRZ, Howell KB. et al. Infantile spasms of unknown cause: predictors of outcome and genotype-phenotype correlation. Pediatr Neurol 2018 pii S0887-8994(18):30346–30341
18 Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52: 3-9
19 Gataullina S, Dulac O. Is epilepsy the cause of comorbidities in Dravet syndrome?. Dev Med Child Neurol 2018; 60: 8
20 Nabbout R, Chemaly N, Chipaux M. et al Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis 2013; 8: 176
21 Bureau M, Dalla Bernardina B. Electroencephalographic characteristics of Dravet syndrome. Epilepsia 2011; 52: 13-23
22 Jensen HS, Grunnet M, Bastlund JF. Therapeutic potential of Na(V)1.1 activators. Trends Pharmacol Sci 2014; 35: 113-118
23 Balagura G, Cacciatore M, Grasso EA. et al Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs 2020; 34: 1001-1007
24 Lagae L. Dravet syndrome. Curr Opin Neurol 2021; 34: 213-218 doi: 10.1097/WCO.0000000000000902
25 Barba C, Parrini E, Coras R. et al Co-occurring malformations of cortical development and SCN1A gene mutations. Epilepsia 2014; 55: 1009-1019
26 Tiefes AM, Hartlieb T, Tacke M. et al Mesial Temporal Sclerosis in SCN1A-Related Epilepsy: Two Long-Term EEG Case Studies. Clin EEG Neurosci 2019; 50: 267-272
27 Skjei KL, Church EW, Harding BN. et al Clinical and histopathological outcomes in patients with SCN1A mutations undergoing surgery for epilepsy. J Neurosurg Pediatr 2015; 16: 668-674
28 Cross JH, Auvin S, Falip M. et al Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017; 8: 505
29 Arzimanoglou A, French J, Blume WT. et al Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009; 8: 82-93
30 Lammertse HCA, van Berkel AA, Iacomino M. et al Homozygous STXBP1 variant causes encephalopathy and gain-of-function in synaptic transmission. Brain 2020; 143: 441-451
31 Hammer MF, Wagnon JL, Mefford HC. et al SCN8A-Related Epilepsy with Encephalopathy. 2016 Aug 25. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds) GeneReviews^® [Internet]. Seattle (WA), University of Washington, Seattle; 1993–2021
32 Mastrangelo M. Lennox-Gastaut Syndrome: A State of the Art Review. Neuropediatrics 2017; 48: 143-151
33 Jiang X, Raju PK, D'Avanzo N. et al Both gain-of-function and loss-of-function de novo CACNA1A mutations cause severe developmental epileptic encephalopathies in the spectrum of Lennox-Gastaut syndrome. Epilepsia 2019; 60: 1881-1894
34 Verrotti A, Grasso EA, Cacciatore M. et al. Potential role of brivaracetam in pediatric epilepsy. Acta Neurol Scand 2020
35 Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs 2021
36 Devinsky O, Patel AD, Cross JH. et al GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018; 378: 1888-1897
37 Suller Marti A, Mirsattari SM, MacDougall K. et al Vagus nerve stimulation in patients with therapy-resistant generalized epilepsy. Epilepsy Behav 2020; 111: 107253
38 Landau WM, Kleffner FR. Syndrome of acquired aphasia with convulsive disorder in children. Neurology 1957; 7: 523-530
39 Deonna T. Acquired epileptiform aphasia in children (Landau-Kleffner-Syndrome). J Clin Neurophysiol 1991; 8: 288-298
40 Morell F, Lewine JD, Squires K. Magnetic source imaging in Landau-Kleffner-Syndrome and its LJS loo-alikes. Epilepsia 1995; 32: 13
41 Hoeppner TJ, Morell F, Smith MC. et al The Landau-Kleffner-Syndrome: A perisylvian epilepsy. Epilepsia 1992; 33 (Suppl 3): 122
42 Rismanchi M. The inhibitory effect of functional lesions on eloquent brain areas: from research bench to operating bed. Int J Neurosci 2018; 128: 1022-1029 doi:10.1080/00207454.2018.1458726. 10.1080/00207454.2018.1458726
43 Carvill GL, Regan BM, Yendle SC. et al GRIN2A mutations cause epilepsy aphasia spectrum disorders. Nat Genet 2013; 45: 1073-1076. doi:10.1038/ng.2727
44 Lesca G, Rudolf G, Bruneau N. et al GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013; 45: 1061-1066. doi:10.1038/ng.2726
45 Mefford H, Yendle S, Hsu C. et al Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol 2011; 70: 974-985. doi:10.1002/ana.22645
46 Rudolf G, de Bellescize J, de Saint Martin A. et al Exome sequencing in 57 patients with self-limited focal epilepsies in childhood with typical or atypical presentations suggest novel candidate genes. Eur J Pediatric Neurol 2020; 27: 104-110
47 Bast T, Richter S, Ebinger F. et al Efficacy and tolerability of methylprednisolone pulse therapy in childhood epilepsies other than infantile spasms. Neuropediatrics 2014; 45: 378-385 doi:10.1055/s-0034-1387817
48 Van den Munckhof B, van Dee V, Sagi L. et al Treatment of electrical status epilepticus in sleep: A pooled analysis of 575 cases. Epilepsia 2015; 56: 1738-1746 doi:10.1111/epi.13128
49 Downes M, Greenaway R, Clark M. et al Outcome following multiple subpial transection in Landau-Kleffner syndrome and related regression. Epilepsia 2015; 56: 1760-1766 doi:10.1111/epi.13132